Oral gene therapy for hemophilia B using chitosan-formulated FIX mutants.
about
Gene therapy for hemophiliaExploring the role of polymer structure on intracellular nucleic acid delivery via polymeric nanoparticles.Chitosan-zein nano-in-microparticles capable of mediating in vivo transgene expression following oral delivery.Next generation FIX muteins with FVIII-independent activity for alternative treatment of hemophilia A.Immunology: Oral solutions.
P2860
Oral gene therapy for hemophilia B using chitosan-formulated FIX mutants.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Oral gene therapy for hemophilia B using chitosan-formulated FIX mutants.
@en
Oral gene therapy for hemophilia B using chitosan-formulated FIX mutants.
@nl
type
label
Oral gene therapy for hemophilia B using chitosan-formulated FIX mutants.
@en
Oral gene therapy for hemophilia B using chitosan-formulated FIX mutants.
@nl
prefLabel
Oral gene therapy for hemophilia B using chitosan-formulated FIX mutants.
@en
Oral gene therapy for hemophilia B using chitosan-formulated FIX mutants.
@nl
P2093
P2860
P921
P356
P1476
Oral gene therapy for hemophilia B using chitosan-formulated FIX mutants.
@en
P2093
P2860
P304
P356
10.1111/JTH.12572
P577
2014-06-01T00:00:00Z